Mechanisms of Local Immunoresistance in Glioma

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 17-29

  Albesiano, Emilia ^a   Han, James E ^b   Lim, Michael ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma multiforme; Immunoresistance; Immunotherapy; Oncogenic signaling pathway

Indexed keywords

CORTICOSTEROID; FAS ANTIGEN; FAS LIGAND; GALECTIN 1; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; PROSTAGLANDIN E2; RAPAMYCIN; STAT3 PROTEIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; APOPTOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CLONAL ANERGY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LYMPHOCYTOPENIA; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROSURGERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CYTOKINES; EPITOPES; GLIOMA; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE;

EID: 70450205329     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.08.008     Document Type: Review

References (158)

1. Buckner J.C., et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92 (2001) 420-433
2. Stupp R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
3. Hochberg F.H., and Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 30 (1980) 907-911
4. Louis D.N., and Gusella J.F. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 11 (1995) 412-415
5. Doolittle N.D., Abrey L.E., Bleyer W.A., et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 11 (2005) 421-428
6. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
7. Murphy J., and Sturm E. Conditions determining the transplantability of tissues in the brain. J Exp Med 38 (1923) 183-197
8. Medawar P. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29 (1948) 58-69
9. Lampson L.A., and Hickey W.F. Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 136 (1986) 4054-4062
10. Cserr H.F., and Knopf P.M. In: Keane R., and Hickey W.F. (Eds). Immunology of the nervous system (1997), Oxford University Press, New York
11. Lampson L. In: Youmans J. (Ed). Neurological surgery (2004), WB Saunders Co, Philadelphia
12. Sandberg-Wollheim M., Zweiman B., Levinson A.I., et al. Humoral immune responses within the human central nervous system following systemic immunization. J Neuroimmunol 11 (1986) 205-214
13. Bernheimer H., Lassmann H., and Suchanek G. Dynamics of IgG+, IgA+, and IgM+ plasma cells in the central nervous system of guinea pigs with chronic relapsing experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol 14 (1988) 157-167
14. Levi-Strauss M., and Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol 139 (1987) 2361-2366
15. Hickey W.F., and Kimura H. Graft-vs.-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system. Proc Natl Acad Sci U S A 84 (1987) 2082-2086
16. Hickey W.F. Basic principles of immunological surveillance of the normal central nervous system. Glia 36 (2001) 118-124
17. Hickey W.F., Hsu B.L., and Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 28 (1991) 254-260
18. Sampson J.H., Archer G.E., Ashley D.M., et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93 (1996) 10399-10404
19. Gordon L.B., Nolan S.C., Cserr H.F., et al. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J Immunol 159 (1997) 2399-2408
20. Gordon F.L., Nguyen K.B., White C.A., et al. Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. J Neuroimmunol 112 (2001) 15-27
21. Parney I.F., Farr-Jones M.A., Chang L.J., et al. Human glioma immunobiology in vitro: implications for immunogene therapy. Neurosurgery 46 (2000) 1169-1177 [discussion: 1177-8]
22. Lampson L.A. Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Microsc Res Tech 32 (1995) 267-285
23. Zuber P., Kuppner M.C., and De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18 (1988) 1623-1626
24. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20 (1997) 165-177
25. Facoetti A., Nano R., Zelini P., et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 11 (2005) 8304-8311
26. Chang C.C., Campoli M., and Ferrone S. HLA class I defects in malignant lesions: what have we learned?. Keio J Med 52 (2003) 220-229
27. Wintterle S., Schreiner B., Mitsdoerffer M., et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63 (2003) 7462-7467
28. Hussain S.F., and Heimberger A.B. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther 5 (2005) 777-790
29. Schartner J.M., Hagar A.R., Van Handel M., et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51 (2005) 279-285
30. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4 (2004) 336-347
31. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2 (2002) 116-126
32. Butte M.J., Keir M.E., Phamduy T.B., et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27 (2007) 111-122
33. Wilmotte R., Burkhardt K., Kindler V., et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 16 (2005) 1081-1085
34. Parsa A.T., Waldron J.S., Panner A., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 (2007) 84-88
35. Yao Y., Tao R., Wang X., et al. B7-H1 is correlated with the malignancy grade of gliomas but it is not the privilege of tumor stem-like cells. Neuro Oncol (2009) [Epub ahead of print]
36. Brooks W.H., Netsky M.G., Normansell D.E., et al. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136 (1972) 1631-1647
37. Mahaley Jr. M.S., Brooks W.H., Roszman T.L., et al. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 46 (1977) 467-476
38. Young H.F., Sakalas R., and Kaplan A.M. Inhibition of cell-mediated immunity in patients with brain tumors. Surg Neurol 5 (1976) 19-23
39. Elliott L.H., Brooks W.H., and Roszman T.L. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132 (1984) 1208-1215
40. Ausiello C.M., Palma C., Maleci A., et al. Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients. Eur J Cancer 27 (1991) 646-650
41. Roszman T.L., Brooks W.H., Steele C., et al. Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. J Immunol 134 (1985) 1545-1550
42. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
43. Liyanage U.K., Moore T.T., Joo H.G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 (2002) 2756-2761
44. Fecci P.E., Mitchell D.A., Whitesides J.F., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 (2006) 3294-3302
45. Gerosa M.A., Olivi A., Rosenblum M.L., et al. Impaired immunocompetence in patients with malignant gliomas: the possible role of Tg-lymphocyte subpopulations. Neurosurgery 10 (1982) 571-573
46. Thornton A.M., and Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287-296
47. Camara N.O., Sebille F., and Lechler R.I. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 33 (2003) 3473-3483
48. Piccirillo C.A., and Shevach E.M. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167 (2001) 1137-1140
49. Dieckmann D., Bruett C.H., Ploettner H., et al. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. [corrected]. J Exp Med 196 (2002) 247-253
50. Zheng S.G., Wang J.H., Koss M.N., et al. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 172 (2004) 1531-1539
51. Munn D.H., Sharma M.D., Lee J.R., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 (2002) 1867-1870
52. Talmadge J.E., Donkor M., and Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26 3-4 (2007) 373-400
53. Munn D.H., Shafizadeh E., Attwood J.T., et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189 (1999) 1363-1372
54. Hwu P., Du M.X., Lapointe R., et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164 (2000) 3596-3599
55. Kudo Y., Boyd C.A., Sargent I.L., et al. Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation. J Physiol 535 (2001) 207-215
56. Frumento G., Rotondo R., Tonetti M., et al. T cell proliferation is blocked by indoleamine 2,3-dioxygenase. Transplant Proc 33 (2001) 428-430
57. Grohmann U., Orabona C., Fallarino F., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3 (2002) 1097-1101
58. Bronte V., Serafini P., Apolloni E., et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 24 (2001) 431-446
59. Kusmartsev S., and Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174 (2005) 4880-4891
60. Zea A.H., Rodriguez P.C., Atkins M.B., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65 (2005) 3044-3048
61. Umemura N., Saio M., Suwa T., et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83 (2008) 1136-1144
62. Turkson J., Zhang S., Palmer J., et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3 (2004) 1533-1542
63. Barshes N.R., Goodpastor S.E., and Goss J.A. Pharmacologic immunosuppression. Front Biosci 9 (2004) 411-420
64. Lesniak M.S., Gabikian P., Tyler B.M., et al. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 70 (2004) 23-28
65. Guha A., and Mukherjee J. Advances in the biology of astrocytomas. Curr Opin Neurol 17 (2004) 655-662
66. Maxwell M., Galanopoulos T., Neville-Golden J., et al. Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76 (1992) 799-804
67. Fontana A., Hengartner H., de Tribolet N., et al. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132 (1984) 1837-1844
68. Govinden R., and Bhoola K.D. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 98 (2003) 257-265
69. Ranges G.E., Figari I.S., Espevik T., et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 166 (1987) 991-998
70. Gorelik L., and Flavell R.A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12 (2000) 171-181
71. Letterio J.J., and Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 16 (1998) 137-161
72. Smyth M.J., Strobl S.L., Young H.A., et al. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol 146 (1991) 3289-3297
73. Kortylewski M., Xin H., Kujawski M., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11 (2005) 1314-1321
74. Resnicoff M., Sell C., Rubini M., et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54 (1994) 2218-2222
75. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 77 (2005) 3-15
76. Hishii M., Nitta T., Ishida H., et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37 (1995) 1160-1166 [discussion: 1166-7]
77. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345-352
78. Huettner C., Czub S., Kerkau S., et al. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17 (1997) 3217-3224
79. Berman R.M., Suzuki T., Tahara H., et al. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 157 (1996) 231-238
80. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 (2004) 97-105
81. Wang D., and Dubois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
82. Baxevanis C.N., Reclos G.J., Gritzapis A.D., et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72 (1993) 491-501
83. Maity A., Pore N., Lee J., et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 60 (2000) 5879-5886
84. Steiner H.H., Karcher S., Mueller M.M., et al. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 66 (2004) 129-138
85. Cheng S.Y., Nagane M., Huang H.S., et al. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A 94 (1997) 12081-12087
86. Ziemer L.S., Koch C.J., Maity A., et al. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia 3 (2001) 500-508
87. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096-1103
88. Munn D.H., and Mellor A.L. IDO and tolerance to tumors. Trends Mol Med 10 (2004) 15-18
89. Uyttenhove C., Pilotte L., Theate I., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1269-1274
90. Miyazaki T., Moritake K., Yamada K., et al. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. J Neurosurg 111 2 (2009) 230-237
91. Rao R.D., and James C.D. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin Oncol 31 (2004) 595-604
92. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 109 (2002) 1139-1142
93. Bromberg J., and Darnell Jr. J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 (2000) 2468-2473
94. Yu C.L., Meyer D.J., Campbell G.S., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269 (1995) 81-83
95. Rahaman S.O., Harbor P.C., Chernova O., et al. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21 (2002) 8404-8413
96. Rahaman S.O., Vogelbaum M.A., and Haque S.J. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res 65 (2005) 2956-2963
97. Konnikova L., Kotecki M., Kruger M.M., et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3 (2003) 23
98. Wang T., Niu G., Kortylewski M., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 (2004) 48-54
99. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263-274
100. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
101. Liu V.C., Wong L.Y., Jang T., et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178 (2007) 2883-2892
102. Hussain S.F., Yang D., Suki D., et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8 (2006) 261-279
103. Hussain S.F., Kong L.Y., Jordan J., et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67 (2007) 9630-9636
104. Kryczek I., Wei S., Zou L., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178 (2007) 6730-6733
105. Weaver C.T., Harrington L.E., Mangan P.R., et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
106. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116 (2006) 1218-1222
107. Harris T.J., Grosso J.F., Yen H.R., et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 179 (2007) 4313-4317
108. Langowski J.L., Zhang X., Wu L., et al. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
109. Cho M.L., Kang J.W., Moon Y.M., et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176 (2006) 5652-5661
110. Kortylewski M., Xin H., Kujawski M., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15 (2009) 114-123
111. Itoh N., Yonehara S., Ishii A., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66 (1991) 233-243
112. Krammer P.H. CD95's deadly mission in the immune system. Nature 407 (2000) 789-795
113. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
114. Shinohara H., Yagita H., Ikawa Y., et al. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 60 (2000) 1766-1772
115. Saas P., Walker P.R., Hahne M., et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J Clin Invest 99 (1997) 1173-1178
116. Walker P.R., Saas P., and Dietrich P.Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 158 (1997) 4521-4524
117. Husain N., Chiocca E.A., Rainov N., et al. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 95 (1998) 287-290
118. Gastman B.R., Atarshi Y., Reichert T.E., et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59 (1999) 5356-5364
119. Badie B., Schartner J., Prabakaran S., et al. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol 120 (2001) 19-24
120. Mabrouk I., Buart S., Hasmim M., et al. Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells. Immunity 29 (2008) 922-933
121. Hahne M., Rimoldi D., Schroter M., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274 (1996) 1363-1366
122. O'Connell J., O'Sullivan G.C., Collins J.K., et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184 (1996) 1075-1082
123. Whiteside T.L. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 12 (2002) 43-50
124. Andreola G., Rivoltini L., Castelli C., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195 (2002) 1303-1316
125. Vaux D.L. Immunology. Ways around rejection. Nature 394 (1998) 133
126. Lau H.T., Yu M., Fontana A., et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273 (1996) 109-112
127. Allison J., Georgiou H.M., Strasser A., et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci U S A 94 (1997) 3943-3947
128. Kang S.M., Schneider D.B., Lin Z., et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3 (1997) 738-743
129. Kang S.M., Lin Z., Ascher N.L., et al. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection. Transplant Proc 30 (1998) 538
130. Kang S.M., Hoffmann A., Le D., et al. Immune response and myoblasts that express Fas ligand. Science 278 (1997) 1322-1324
131. Restifo N.P. Countering the 'counterattack' hypothesis. Nat Med 7 (2001) 259
132. Simon A.K., Gallimore A., Jones E., et al. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2 (2002) 315-322
133. Green D.R., and Ferguson T.A. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2 (2001) 917-924
134. O'Connell J., Houston A., Bennett M.W., et al. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 7 (2001) 271-274
135. Xia S., Rosen E.M., and Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Res 65 (2005) 5248-5255
136. Giraud S., Bessette B., Boda C., et al. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. Int J Oncol 30 (2007) 273-281
137. Roth W., Isenmann S., Nakamura M., et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61 (2001) 2759-2765
138. Wei J., DeAngulo G., Sun W., et al. Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother 58 (2009) 259-270
139. Fortin S., Le Mercier M., Camby I., et al. Galectin-1 is implicated in the protein kinase C epsilon/Vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells. Brain Pathol (2008) [Epub ahead of print]
140. Camby I., Le Mercier M., Lefranc F., et al. Galectin-1: a small protein with major functions. Glycobiology 16 (2006) 137R-157R
141. Camby I., Belot N., Rorive S., et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11 (2001) 12-26
142. Camby I., Belot N., Lefranc F., et al. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61 (2002) 585-596
143. Jung T.Y., Jung S., Ryu H.H., et al. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg 109 (2008) 273-284
144. Rorive S., Belot N., Decaestecker C., et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33 (2001) 241-255
145. Le Mercier M., Lefranc F., Mijatovic T., et al. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229 (2008) 172-183
146. Le Mercier M., Mathieu V., Haibe-Kains B., et al. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67 (2008) 456-469
147. Rubinstein N., Alvarez M., Zwirner N.W., et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004) 241-251
148. Toscano M.A., Ilarregui J.M., Bianco G.A., et al. Dissecting the pathophysiologic role of endogenous lectins: glycan-binding proteins with cytokine-like activity?. Cytokine Growth Factor Rev 18 (2007) 57-71
149. Rabinovich G.A., Baum L.G., Tinari N., et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. Trends Immunol 23 (2002) 313-320
150. Liu F.T. Galectins: a new family of regulators of inflammation. Clin Immunol 97 (2000) 79-88
151. Perillo N.L., Pace K.E., Seilhamer J.J., et al. Apoptosis of T cells mediated by galectin-1. Nature 378 (1995) 736-739
152. Rabinovich G.A., Ramhorst R.E., Rubinstein N., et al. Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms. Cell Death Differ 9 (2002) 661-670
153. Rabinovich G.A., Iglesias M.M., Modesti N.M., et al. Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J Immunol 160 (1998) 4831-4840
154. Blaser C., Kaufmann M., Muller C., et al. Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 28 (1998) 2311-2319
155. Chung C.D., Patel V.P., Moran M., et al. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165 (2000) 3722-3729
156. Rabinovich G.A., Daly G., Dreja H., et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 190 (1999) 385-398
157. Rabinovich G.A., Ariel A., Hershkoviz R., et al. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97 (1999) 100-106
158. Le Q.T., Shi G., Cao H., et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23 (2005) 8932-8941